Picture loading failed.

Anti-MS4A1 therapeutic antibody (Pre-made Ocrelizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Ocrelizumab, sold under the brand name Ocrevus, is a pharmaceutical drug for the treatment of multiple sclerosis (MS). It is a humanized anti-CD20 monoclonal antibody.[3] It targets CD20 marker on B lymphocytes and hence is an immunosuppressive drug.[4] Ocrelizumab binds to an epitope that overlaps with the epitope to which rituximab binds.[4]

Order informatioin

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-389-1mg 1mg 3090
GMP-Bios-ab-389-10mg 10mg 21890
GMP-Bios-ab-389-100mg 100mg 148000
GMP-Bios-ab-389-xmg >100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-MS4A1 therapeutic antibody (Pre-made Ocrelizumab biosimilar,Whole mAb)
INN Name Ocrelizumab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusNFD
100% SI StructureNone
99% SI StructureNone
95-98% SI Structure4k7p:YX
Year Proposed2005
Year Recommended2006
CompaniesBiogen;Biogen Idec;Chugai Pharmaceutical;Genentech;Roche
Conditions ApprovedMultiple sclerosis
Conditions Activena
Conditions DiscontinuedEye disorders;Haematological malignancies;Lupus nephritis;Rheumatoid arthritis;Systemic lupus erythematosus
Development Techna